Literature DB >> 6158882

Adjuvant chemotherapy in the treatment of advanced tumors of the head and neck.

M B Spaulding, D Klotch, J Grillo, S Sanani, J M Loré.   

Abstract

In May 1978 a multimodal approach was begun for the management of patients with squamous cell carcinoma of the head and neck who presented with stage III and IV disease and whose chance of control by surgery alone was estimated to be 20 percent or less. Twenty-eight patients received two courses of chemotherapy consisting of cis-diamminedichloro platinum, vincristine and infusion bleomycin before undergoing surgery. The clinical response to this therapy judged preoperatively was surprisingly high. Three patients had no histologic evidence of tumor in the resected specimens, and toxicity was minimal. Twenty-five patients were treated surgically. No pre- or postoperative complications were attributable to chemotherapy. Three patients were treated with radiation therapy, one of whom died at 12 months with recurrent disease. Two patients died from causes unrelated to the tumor. Two patients have had recurrence of tumor. All others remain free of disease with follow-up of up ot 18 months.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158882     DOI: 10.1016/0002-9610(80)90207-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Update in cancer chemotherapy: head and neck cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-11       Impact factor: 1.798

2.  Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.

Authors:  Hisataka Kitano; Yoh Masaoka; Atsushi Mamiya; Yusuke Fujiwara; Toshio Miki; Chiaki Hidai
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  In vitro antagonism between cisplatin and vinca alkaloids.

Authors:  K Lee; M Tanaka; H Kanamaru; T Hashimura; I Yamamoto; J Konishi; F Kuze
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.